137 related articles for article (PubMed ID: 38384077)
1. A rare case of miliary tuberculosis in a patient with NSCLC receiving PD1 inhibitor therapy, mimicking autoimmune pneumonitis.
Nikola N; Natasa D; Milica K
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S909-S911. PubMed ID: 38384077
[TBL] [Abstract][Full Text] [Related]
2. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
[TBL] [Abstract][Full Text] [Related]
6. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
7. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
8. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
9. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
10. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
[TBL] [Abstract][Full Text] [Related]
12. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
[TBL] [Abstract][Full Text] [Related]
14. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
[TBL] [Abstract][Full Text] [Related]
17. Chronic immune checkpoint inhibitor pneumonitis.
Naidoo J; Cottrell TR; Lipson EJ; Forde PM; Illei PB; Yarmus LB; Voong KR; Feller-Kopman D; Lee H; Riemer J; Wang D; Taube JM; Brahmer JR; Lin CT; Danoff SK; D'Alessio FR; Suresh K
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554618
[TBL] [Abstract][Full Text] [Related]
18. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
